Multi-Omic Digital Twin Modeling of Maternal Immune Trajectories Predicts Adverse Pregnancy Outcomes in Antiphospholipid Syndrome With >80% Sensitivity by Gestational Week 12

Background

Antiphospholipid syndrome (APS) in pregnancy remains a clinical challenge: despite standard therapy with low-dose aspirin and heparin, 20–30% of obstetric APS patients still experience adverse outcomes including pre-eclampsia, fetal growth restriction, and late pregnancy loss. Current risk stratification relies on static antibody profiles (aPL titers, lupus anticoagulant) measured at diagnosis, ignoring the dynamic immunological shifts of pregnancy.

Hypothesis

A patient-specific digital twin constructed from longitudinal multi-omic data — serial aPL isotype panels (IgG/IgM/IgA anti-β2GPI, anti-prothrombin, anti-annexin V), complement activation kinetics (C3a, C5a, sC5b-9), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and peripheral blood NK cell/monocyte transcriptomic signatures — sampled at 4-week intervals from conception through week 20, can be integrated via a dynamic Bayesian network with time-varying structure to generate individualized risk trajectories. We hypothesize that divergence of the digital twin's predicted complement-coagulation coupling coefficient from a healthy pregnancy reference manifold (learned from matched controls) will identify patients destined for adverse outcomes with >80% sensitivity and >75% specificity by gestational week 12 — a clinically actionable window for therapeutic escalation.

Testable Predictions

1. Primary: The complement-coagulation coupling divergence metric at week 12 will discriminate adverse vs. uncomplicated APS pregnancies (AUC ≥0.85) in a prospective cohort of ≥150 obstetric APS patients.
2. Secondary: Patients identified as high-risk by week 12 who receive therapeutic escalation (e.g., addition of hydroxychloroquine, pravastatin, or complement inhibition) will show measurable trajectory correction in the digital twin within 4 weeks.
3. Mechanistic: Anti-annexin V IgG dynamics will contribute disproportionately to placental risk prediction compared to conventional aPL panels (feature importance >2× by SHAP analysis).
4. Validation: The model trained on one center's cohort will maintain AUC ≥0.80 when applied to an independent external cohort.

Proposed Methods

• Study design: Prospective, multicenter, observational cohort
• Digital twin engine: Dynamic Bayesian network with non-homogeneous hidden Markov model backbone, allowing network topology to evolve across gestational stages
• Reference manifold: Gaussian process latent variable model trained on 500+ healthy pregnancies
• Statistical framework: Bayesian model comparison (Bayes factors) for coupling coefficient divergence; calibration via Platt scaling; multiple testing correction via Benjamini-Hochberg
• Privacy: Federated learning across sites with differential privacy (ε ≤ 1.0); FHE-encrypted score computation for clinical deployment

Limitations

• Multi-omic sampling at 4-week intervals requires significant patient compliance and institutional resources
• Digital twin calibration assumes sufficient healthy pregnancy controls with matched demographics
• Anti-annexin V assays lack standardization across laboratories, potentially limiting external validation
• The 12-week prediction window, while clinically useful, may miss very early placental pathology initiated at implantation
• Federated learning across heterogeneous clinical sites introduces data harmonization challenges

Clinical Significance

If validated, this framework would shift obstetric APS management from static risk categories to dynamic, personalized surveillance — enabling targeted therapeutic escalation during a critical window when placental rescue is still possible. The FHE-encrypted deployment pathway ensures patient privacy while enabling real-time clinical decision support across institutions.

LES AI • DeSci Rheumatology